abstract: UNASSIGNED: The strengths of noncovalent interactions are generally very sensitive to a number of geometric parameters. Among the most important of these parameters is the separation between the interacting moieties (in the case of an intermolecular interaction, this would be the intermolecular separation). Most works seeking to characterize the properties of intermolecular interactions are mainly concerned with binding energies obtained at the potential energy minimum (as determined at some particular level of theory). In this work, in order to extend our understanding of these types of noncovalent interactions, we investigate the distance dependence of several types of intermolecular interactions, these are @entity3884 bonds, stacking interactions, dispersion interactions, and X-H         interactions. There are several methods that have traditionally been used to treat noncovalent interactions as well as many new methods that have emerged within the past three or four years. Here we obtain reference data using estimated CCSD(T) values at the complete basis set limit (using the CBS(T) method); potential energy curves are also produced using several other methods thought to be accurate for intermolecular interactions, these are @entity4885 /cc-pVTZ, @entity4885 /aug-cc-pVDZ, @entity4885 /6-31G*(0.25), @entity4886 (MI)- @entity4885 /cc-pVTZ, estimated @entity4887 /CBS, DFT-SAPT/aug-cc-pVTZ, DFT/M06-2X/6-311+G(2df,2p), and DFT-D/TPSS/6-311++G(3df,3pd). The basis set superposition error is systematically considered throughout the study. It is found that the @entity4887 and DFT-SAPT methods, which are both quite computationally intensive, produce potential energy curves that are in very good agreement to those of the reference method. Among the @entity4885 techniques, which can be said to be of medium computational expense, the best results are obtained with @entity4885 /cc-pVTZ and @entity4886 (MI)- @entity4885 /cc-pVTZ. DFT-D/TPSS/6-311++G(3df,3pd) is the DFT-based method that can be said to give the most well-balanced description of intermolecular interactions.

title: On the Structure and Geometry of Biomolecular Binding Motifs ( XXXX -Bonding, Stacking, X-H        ): WFT and DFT Calculations.

entities_list: @entity3884 :: ('MESH:D006859', 'Chemical') :: ['hydrogen']

answer: @entity3884 :: (MESH:D006859,Chemical) :: ['Hydrogen']


abstract: Forty-three psoriatic @entity1 with spondylitic involvement (19 @entity1 and 24 @entity1 , mean age 41 years) have been reviewed. Three different subsets were recognized. The first ( @entity13769 ), with predominant involvement of the axial skeleton, occurred in 22 (seven @entity1 and 15 @entity1 , mean age 39). The second ( @entity13770 ) and the third ( @entity18383 ) showed an overlap of @entity1511 and @entity1897 . In @entity13770 this consisted of @entity571 ( @entity571 ) @entity625 (five @entity1 and three @entity1 , mean age 41), while in @entity18383 there was symmetrical @entity625 (seven @entity1 and six @entity1 , mean age 42). Spinal involvement, present in every case, was characterized by unilateral and asymmetrical syndesmophytes, often nonmarginal and randomly affecting the vertebral column. @entity6592 , absent in the @entity13770 subset, was present in 15 of the @entity13769 and in two of the @entity18383 subgroup and was bilateral in six and unilateral in 11. The @entity1530 antigen, absent in the @entity13770 subgroup, was found in 12 of the @entity13769 and in two of the @entity18383 subset. It was associated with @entity6592 in 13 cases and with @entity1511 without @entity6592 in only one case. Nail changes were recorded in 30% of the total cases and showed a strict relationship with the @entity13770 subset (40%). Extra-articular symptoms, consisting almost exclusively of ocular involvement, occurred in three @entity1 only (two cases of @entity2024 and one of @entity6990 ). The clinical course of @entity1511 appeared @entity717 than that of the idiopathic form.

title: The clinical spectrum of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men']

entities_list: @entity6592 :: ('MESH:D058566', 'Disease') :: ['Sacroiliitis', 'sacroiliitis']

entities_list: @entity6990 :: ('MESH:D014606', 'Disease') :: ['acute anterior uveitis']

entities_list: @entity571 :: ('MESH:D010003', 'Disease') :: ['DIP', 'distal interphalangeal']

entities_list: @entity625 :: ('MESH:D001168', 'Disease') :: ['arthritis', 'polyarthritis']

entities_list: @entity1511 :: ('MESH:D013166', 'Disease') :: ['spondylitis', 'psoriatic spondylitis']

entities_list: @entity1897 :: ('MESH:D010523', 'Disease') :: ['peripheral articular disease']

entities_list: @entity2024 :: ('MESH:D003231', 'Disease') :: ['conjunctivitis']

entities_list: @entity717 :: ('MESH:D009069', 'Disease') :: ['less disabling']

answer: @entity1511 :: (MESH:D013166,Disease) :: ['psoriatic spondylitis']


abstract: UNASSIGNED: Emerging evidence indicates that @entity9017 / @entity9018 signaling is involved in @entity1118 . However, few studies have systemically assessed its role in direct nerve injury-induced @entity9 and the underlying mechanism. Here, we determined that @entity128 ( @entity128 ) increased the expression of @entity9017 and its cognate receptor @entity9018 in lumbar 5 dorsal root ganglia (DRG) neurons and satellite glial cells. @entity128 also induced long-lasting upregulation of @entity9017 and @entity9018 in the ipsilateral L4-5 spinal cord dorsal horn, characterized by @entity9017 expression in neurons and microglia, and @entity9018 expression in neurons and astrocytes. Moreover, @entity128 -induced a sustained increase in @entity1505 expression in the DRG and spinal cord. Intraperitoneal injection (i.p.) of the @entity1505 synthesis inhibitor @entity2816  reduced the @entity128 -induced mechanical @entity56 and inhibited the expression of @entity9017 in the DRG and spinal cord. Intrathecal injection (i.t.) of the @entity9018 antagonist @entity9019 , both 30  min before and 7  days after @entity128 , reduced the behavioral signs of @entity1931 . @entity35 given an i.t. or i.p. bolus of @entity9019 on day 8 of @entity128 exhibited attenuated abnormal @entity158 . The @entity9 established following @entity128 was also impaired by i.t. administration of a @entity9017 -neutralizing antibody. Moreover, repetitive i.t. @entity9019 administration prevented the activation of @entity2509 in the spinal cord. The mechanical @entity56 induced in na  ve @entity35 by i.t. @entity9017 was alleviated by pretreatment with the MEK inhibitor @entity4286 . Collectively, our results revealed that @entity1505 might mediate the upregulation of @entity9017 in the DRG and spinal cord following @entity128 , and that @entity9017 / @entity9018 signaling via @entity2509 activation contributes to the development and maintenance of @entity9 .

title: Upregulation of Chemokine @entity9017 in the Dorsal Root Ganglia and Spinal Cord Contributes to the Development and Maintenance of XXXX Following Spared Nerve Injury in @entity35 .

entities_list: @entity1931 :: ('MESH:D006930', 'Disease') :: ['allodynia']

entities_list: @entity2816 :: ('MESH:D013792', 'Chemical') :: ['thalidomide']

entities_list: @entity128 :: ('MESH:D020209', 'Disease') :: ['spared nerve injury', 'SNI']

entities_list: @entity56 :: ('MESH:D004342', 'Disease') :: ['hypersensitivity']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['pain behaviors']

entities_list: @entity1118 :: ('MESH:D059350', 'Disease') :: ['chronic pain']

entities_list: @entity9 :: ('MESH:D009437', 'Disease') :: ['neuropathic pain']

answer: @entity9 :: (MESH:D009437,Disease) :: ['Neuropathic Pain']


abstract: OBJECTIVE: To evaluate ascertainment of the onset of community transmission of @entity683 ( @entity1707 flu) in England during the earliest phase of the epidemic through comparing data from two surveillance systems. DESIGN: Cross sectional opportunistic survey. STUDY SAMPLES: Results from self samples by consenting @entity1 who had called the NHS Direct telephone health line with @entity1109 , or both, and results from Health Protection Agency (HPA) regional microbiology laboratories on @entity1 tested according to the clinical algorithm for the management of suspected cases of @entity1707 flu. SETTING: Six regions of England between 24 May and 30 June 2009. MAIN OUTCOME MEASURE: Proportion of specimens with laboratory evidence of @entity683 . RESULTS: Influenza A/H1N1 2009 infections were detected in 91 (7%) of the 1385 self sampled specimens tested. In addition, eight instances of @entity281 and two cases of @entity2623 were detected. The weekly rate of change in the proportions of infected individuals according to self obtained samples closely matched the rate of increase in the proportions of infected @entity1 reported by HPA regional laboratories. Comparing the data from both systems showed that local community transmission was occurring in London and the West Midlands once HPA regional laboratories began detecting 100 or more @entity281 , or a proportion positive of over 20% of those tested, each week. CONCLUSIONS: Trends in the proportion of @entity1 with @entity683 across regions detected through clinical management were mirrored by the proportion of NHS Direct callers with laboratory confirmed @entity281 . The initial concern that information from HPA regional laboratory reports would be too limited because it was based on testing @entity1 with either travel associated risk or who were contacts of other @entity683 cases was unfounded. Reports from HPA regional laboratories could be used to recognise the extent to which local community transmission was occurring.

title: Monitoring the emergence of community transmission of XXXX in England: a cross sectional opportunistic survey of self sampled telephone callers to NHS Direct.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'people']

entities_list: @entity1109 :: ('MESH:D012678', 'Disease') :: ['cold or flu symptoms']

entities_list: @entity683 :: ('MESH:D007251', 'Disease') :: ['influenza', 'influenza A/H1N1 2009']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection', 'influenza A/H3 infection', 'influenza A/H1N1 2009 infections']

entities_list: @entity2623 :: ('MESH:C531629', 'Disease') :: ['influenza B infection']

answer: @entity683 :: (MESH:D007251,Disease) :: ['influenza A/H1N1 2009']


abstract: Thrombolytic therapy has been used for treating @entity1 suffering from a variety of clinical disorders including @entity1 suffering from extensive venous and arterial @entity715 . This paper describes a combined approach to lytic therapy consisting of administration of small doses of streptokinase in combination with the infusion of plasminogen. The rationale for this approach is based on recent observations that additional plasminogen will be absorbed into preformed thrombi, rendering them more susceptible to lysis in the presence of activators. Forty-four @entity1 who presented with symptoms and signs of acute or sub-acute @entity1150 ( @entity1150 ) confirmed by phlebography, were included in this study. Group I: 15 consecutive @entity1 received an infusion of 600,000 units of SK dissolved in 50 ml of physiological saline over a period of half and hour. On the subsequent 4 days, a dose of 300,000 units was given twice daily. Group II: 29 consecutive @entity1 received 60 to 90 mg of pretreated plasminogen dissolved in 50 ml of saline given intravenously over 30 min. and followed by same dosage regimen of SK. Blood samples were taken at varying intervals to assess changes in the haemostatic parameters. These were analysed for levels of alpha 2-antiplasmin, antithrombin III, @entity2002 , plasminogen, @entity2002 and degradation products, fibrinolytic activity and levels of activator complex. Findings observed will be presented. Phlebograms were performed before starting treatment and were repeated at the end of 5 days when the treatment had finished. In Group I--(15 @entity1 )--thrombi remained virtually unchanged in 12 out of 15 @entity1 receiving streptokinase infusion; in 3 (20%) there was partial but extensive lysis. In contrast, in Group II--(29 @entity1 )--in 16 (55%) of 29 @entity1 receiving plasminogen and streptokinase infusion, complete lysis of thrombi was obtained. Seven (24%) showed extensive clearance of venous tree while in remaining 6, thrombi virtually remained unchanged.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Intermittent plasminogen-streptokinase treatment of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis']

entities_list: @entity1150 :: ('MESH:D020246', 'Disease') :: ['deep vein thrombosis', 'DVT']

answer: @entity1150 :: (MESH:D020246,Disease) :: ['deep vein thrombosis']


abstract: @entity205 's known regulatory effects on the immune system suggest that it may be useful in treating @entity1 with @entity8 . A randomised prospective single blind study of 19 @entity1 with @entity8 and @entity644 (greater than 1.5 g/day) was conducted to determine the therapeutic value of @entity205 . The @entity1 were divided into two groups: nine @entity1 were given oral @entity205 (5 mg/kg/day) for 12 weeks and 10 @entity1 a placebo. The two groups were comparable in age of presentation, ratio of @entity1 to @entity1 , plasma @entity1011 and serum IgA concentrations, @entity1011 clearance, daily urinary protein excretion, severity of renal histopathological changes, and prevalence of @entity101 . A significant reduction of @entity644 and an increase of plasma albumin concentration was observed with treatment with @entity205 . Nevertheless, a significant rise of plasma @entity1011 concentration and a fall in @entity1011 clearance was found in @entity1 after six weeks' treatment with @entity205 , although the plasma @entity205 concentrations were maintained within a narrow therapeutic range. Serum IgA concentrations were reduced in seven @entity1 . Renal function improved within eight weeks after treatment was stopped. Three months after treatment was stopped @entity644 remained less than half of the pretreatment values in three @entity1 . No similar biochemical changes were observed in the controls. Short term @entity205 therapy may be beneficial in reducing @entity644 in some @entity1 with @entity8 . As transient @entity8 was seen, despite @entity205 concentrations being maintained within a narrow therapeutic range, indiscriminate use of @entity205 in @entity631 should be discouraged.

title: @entity205 treatment of XXXX : a short term controlled trial.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men']

entities_list: @entity644 :: ('MESH:D011507', 'Disease') :: ['proteinuria']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['IgA nephropathy', 'renal impairment']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity205 :: ('MESH:D016572', 'Chemical') :: ['Cyclosporin', 'cyclosporin']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']

entities_list: @entity631 :: ('MESH:D005921', 'Disease') :: ['glomerulonephritis']

answer: @entity8 :: (MESH:D007674,Disease) :: ['IgA nephropathy']


abstract: @entity1267 ( @entity3747 ) is most likely to affect dairy @entity291 around the time of parturition. It causes progressive @entity4094 and flaccid @entity912 . Older dairy @entity291 , @entity291 with a history of @entity1267 during a previous lactation, high-producing @entity291 , and @entity291 from the Jersey and Guernsey breeds are at highest risk for developing @entity1267 . Nonparturient @entity3747 may also occur and is related to events other than parturition, such as severe stress, that temporarily overwhelm the mechanisms of @entity460 homeostasis. Beef @entity291 , @entity742 , and @entity1237 are affected less frequently by @entity3747 than are dairy @entity291 . Because these species are not as stressed for milk production as dairy @entity291 , nonparturient @entity3747 makes up a higher proportion of cases in nondairy ruminants. Clinical signs of @entity3747 in beef @entity291 , @entity742 , and @entity1237 tend toward hyperesthesia and @entity116 rather than the classic flaccid @entity912 that occurs in dairy @entity291 with parturient @entity3747 . Prompt and effective treatment of @entity3747 helps to reduce the incidence of secondary complications, such as @entity121 or @entity1271 . The standard treatment regimen of 500 ml of 23 per cent @entity10041 , administered intravenously, will elicit a favorable response in approximately 75 per cent of recumbent @entity291 within 2 hours of treatment. Relapses following successful initial therapy are common and may be prevented in part by supplementation of intravenous treatment with an additional 500 ml of 23 per cent @entity10041 administered subcutaneously. Proper nursing care following treatment speeds recovery and reduces the incidence of secondary complications owing to @entity3747 .

title: @entity1267 and XXXX in ruminant livestock.

entities_list: @entity3747 :: ('MESH:D006996', 'Disease') :: ['hypocalcemia']

entities_list: @entity4094 :: ('MESH:D009468', 'Disease') :: ['neuromuscular dysfunction']

entities_list: @entity121 :: ('MESH:D009135', 'Disease') :: ['muscle damage']

entities_list: @entity1267 :: ('MESH:D010319', 'Disease') :: ['Parturient paresis', 'parturient paresis']

entities_list: @entity10041 :: ('MESH:D002125', 'Chemical') :: ['calcium gluconate']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

entities_list: @entity912 :: ('MESH:D010243', 'Disease') :: ['paralysis']

answer: @entity3747 :: (MESH:D006996,Disease) :: ['hypocalcemia']


abstract: We describe eight cases of primary @entity704 occurring in seven @entity1 and one @entity1 between the ages of 25 and 77 years. Clinically, all @entity1 had initial radiographic findings of a parenchymatous intrapulmonary mass without evidence of mediastinal involvement either radiologically or at surgery. The lesions varied from 0.5 to 10 cm in greatest diameter. Five @entity5 were located close to the hilum, while the other three were discovered deep within the lung and in subpleural locations. In one case, the lesion appeared to arise endobronchially and infiltrate the surrounding parenchyma. In another case, in addition to the main hilar mass, there were two smaller @entity5 nodules found deep within the same lung. Histologically, the lesions were characterized by the classic biphasic cellular composition of @entity704 , i.e., an admixture in varying proportions of epithelial cells and lymphocytes. Four cases were characterized by sheets of lymphocytes admixed with scattered epithelial cells that were separated by fibrous bands into lobules. Three cases were composed predominantly of sheets of epithelial cells admixed with scattered small lymphocytes and containing prominent perivascular spaces. In two of these cases, focal areas of spindling of the cells were noted. One case was composed predominantly of a spindle cell proliferation with perivascular spaces and numerous small lymphocytes. Immunohistochemical stains for keratin and epithelial membrane antigen in six cases highlighted the epithelial cells scattered against the lymphoid cell background. Seven @entity1 were treated by surgery. In one @entity1 the @entity5 was deemed inoperable at the time of exploration owing to extensive @entity456 and was treated by postoperative radiation; the lesion recurred locally in the pleura 8 years later. Clinical follow-up in three @entity1 after surgical incision showed them to ba alive and well without evidence of disease at 10 months, 2 years, and 8 years, respectively. Two of the @entity1 had been followed clinically for 2 and 4 years following discovery of their lung masses on routine chest radiograph before resection of their @entity5 . Two @entity1 died of unrelated conditions; in one of them, the lesions had been followed clinically for 6 years before surgery; this @entity1 died 6 months later from @entity453 , without evidence of recurrence or @entity3 . Our findings suggest that @entity704 are slow-growing @entity5 that may respond well to surgical resection when confined to the lung. As with their mediastinal counterparts, invasive @entity5 will require additional treatment for the possibility of recurrence of @entity3 .

title: Primary XXXX . A clinicopathologic and immunohistochemical study of eight cases.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient', 'man']

entities_list: @entity704 :: ('MESH:D013945', 'Disease') :: ['thymomas', 'intrapulmonary thymoma', 'intrapulmonary thymomas']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary artery disease']

entities_list: @entity456 :: ('MESH:D010995', 'Disease') :: ['pleural infiltration']

answer: @entity704 :: (MESH:D013945,Disease) :: ['intrapulmonary thymoma']


abstract: OBJECTIVE: Intestinal @entity63 /reperfusion (IR) injury involves activation of inflammatory mediators, @entity39 , ileus, and alteration in a variety of gene products. Ischemic preconditioning ( @entity5524 ) reduced all the effects of @entity1944 seen in IR. In an effort to investigate the molecular mechanisms responsible for the protective effects afforded by @entity5524 , we sought to characterize the global gene expression pattern in @entity35 subjected to @entity5524 in the setting of IR injury. METHODS: @entity35 were randomized into five groups: (1) Sham, (2) @entity5524 only (3) IR, (4) Early @entity5524 + IR ( @entity5524 --> IR), and (5) Late @entity5524 + IR ( @entity5524 --> 24 h --> IR). At 6 h after reperfusion, ileum was harvested for total RNA isolation, pooled, and analyzed on complementary DNA (cDNA) microarrays with validation using real-time polymerase chain reaction (PCR). Significance Analysis of Microarray (SAM) software was used to determine statistically significant changes in gene expression. RESULTS: Early @entity5524 + IR had 5,167 induced and 4 repressed genes compared with the other groups. SAM analysis revealed 474 out of 10,000 genes differentially expressed among the groups. Early and Late @entity5524 + IR had more genes involved in redox hemostasis, the immune/inflammatory response, and apoptosis than either the @entity5524 only or IR alone groups. CONCLUSION: The transcriptional profile suggests that @entity5524 exerts its protective effects by regulating the gene response to injury in the intestine.

title: Intestinal @entity63 preconditioning after @entity63 /reperfusion injury in XXXX intestine: profiling global gene expression patterns.

entities_list: @entity1944 :: ('MESH:D007410', 'Disease') :: ['intestinal injury']

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['mucosal necrosis']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia']

answer: @entity35 :: (10116,Species) :: ['rat']


abstract: @entity3841 produces a leukotoxin that kills @entity1 polymorphonuclear cells (PMNs) and monocytes but not lymphocytes. In this study, we examined A. actinomycetemcomitans leukotoxin for its ability to alter @entity1 peripheral blood lymphocyte (HPBL) responsiveness. After a 90-min exposure to the leukotoxin, all monocytes were killed and HPBL responsiveness to mitogens and antigens was significantly inhibited. The ability of the leukotoxin to inhibit HPBL responses was not surprising, since monocytes and macrophages are required for many lymphocyte functions. However, we were unable to totally restore HPBL responsiveness when adherent autologous monocytes were added back to cultures of leukotoxin-treated lymphocytes. These studies demonstrate that A. actinomycetemcomitans leukotoxin may also exert nonlethal effects directly on lymphocytes. Furthermore, impaired lymphocyte function did not appear to be the result of indirect effects of products released by dying monocytes. Although it is not clear how A. actinomycetemcomitans acts to cause disease, several investigators have proposed that @entity73 may play a pivotal role. Several studies have demonstrated defects in PMN, monocyte, and lymphocyte function in @entity1 with @entity2520 . These findings, along with the data presented in this paper, support the hypothesis that @entity1 who harbor A. actinomycetemcomitans could suffer from @entity1200 . The effects of this suppression may be to enhance the pathogenicity of A. actinomycetemcomitans itself or that of some other opportunistic organism.

title: Immunosuppressive properties of XXXX leukotoxin.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity2520 :: ('MESH:D010510', 'Disease') :: ['periodontal disease']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['impaired host defenses']

entities_list: @entity1200 :: ('MESH:D007154', 'Disease') :: ['local or systemic immune suppression']

entities_list: @entity3841 :: ('714', 'Species') :: ['Actinobacillus actinomycetemcomitans']

answer: @entity3841 :: (714,Species) :: ['Actinobacillus actinomycetemcomitans']


abstract: Between January 1973 and December 1983, 469 @entity1 with @entity1204 were seen at this institution. Eighty-one @entity1 were identified with @entity420 involving both the uterine body and the cervix. @entity1 were divided into three groups for evaluation. Group A (n = 58) had a positive cervical biopsy or endocervical curettage, but a normal-appearing cervix at clinical examination. Group B (n = 18) had gross @entity5 involving the cervix which was confirmed by biopsy. Group C (n = 5) had unsuspected cervical involvement revealed at hysterectomy. Fourteen Group A @entity1 received preoperative radiation therapy. Thirty of the 44 Group A @entity1 (68.2%) who did not receive preoperative radiation, had no involvement of the cervix by @entity5 in the hysterectomy specimen. Seventy-six @entity1 were eligible for follow-up of at least 18 months. There were 24 recurrences among these 76 @entity1 . Recurrence was more common with advancing grade and with increasing myometrial invasion. @entity177 occurred with comparable frequency in both Groups A and B. Only 4 of 11 @entity1 who were found to have extrauterine disease at surgery are still alive. In this study, we found that endocervical curettage has a significant false-positive rate, both histologic grade and volume of cervical involvement should be considered in treatment planning, primary operation should be considered in the management of selected @entity1 with @entity1204 , and extrauterine disease is a grave prognostic factor.

title: XXXX corpus et colli: analysis of diagnostic variables.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity1204 :: ('MESH:D016889', 'Disease') :: ['carcinoma of the endometrium', 'Stage II endometrial carcinoma']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['Pelvic failures']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma']

answer: @entity420 :: (MESH:D000230,Disease) :: ['Adenocarcinoma']


abstract: UNASSIGNED: Identifying the mutated gene that produces a particular @entity3986 is difficult because different genotypes may share a phenotype and vice versa. Muscle MRI is a useful tool to recognize patterns of muscle involvement in @entity1 with @entity3986 and to guide the diagnosis process. The radiologic pattern of muscle involvement in @entity1 with mutations in the EMD and @entity4223 genes has not been completely established. Our objective is to describe the pattern of muscle @entity1560 in @entity1 with mutations in the EMD and in the @entity4223 genes and to search for differences between the two genotypes that could be helpful to guide the genetic tests. We conducted a national multicenter study in 42 @entity1 , 10 with mutations in the EMD gene and 32 with mutations in the @entity4223 gene. MRI or CT was used to study the muscles from trunk to legs. @entity1 had a similar pattern of @entity1560 regardless of whether they had the mutation in the EMD or @entity4223 gene. The main muscles involved were the paravertebral, glutei, @entity121 , biceps, semitendinosus, semimembranosus, adductor major, soleus, and gastrocnemius. Involvement of peroneus muscle, which was more frequently affected in @entity1 with mutations in the EMD gene, was useful to differentiate between the two genotypes. Muscle MRI/CT identifies a similar pattern of muscle @entity1560 in @entity1 with mutations in the EMD or the @entity4223 genes. The involvement of peroneus muscles could be useful to conduct genetic analysis in @entity1 with an EDMD phenotype.

title: Muscle imaging in XXXX produced by mutations in the EMD and @entity4223 genes.

entities_list: @entity1560 :: ('MESH:D005234', 'Disease') :: ['fatty infiltration']

entities_list: @entity3986 :: ('MESH:D009136', 'Disease') :: ['muscle dystrophies', 'muscle dystrophy']

entities_list: @entity121 :: ('MESH:D009135', 'Disease') :: ['quadriceps']

answer: @entity3986 :: (MESH:D009136,Disease) :: ['muscle dystrophies']


abstract: OBJECTIVE: Generic measures of coping fail to capture the process of undergoing specific health processes such as @entity5 genetic risk assessment. The Genetic Risk Assessment Coping Evaluation (GRACE) has been developed to provide greater specificity of measurement. METHOD: Based upon previous research findings, the GRACE measures the degree of stress associated with 11 recognised sources of stress for individuals undergoing the early stages of @entity5 genetic risk assessment, and the use of up to eight coping strategies they may elicit. This paper reports preliminary data from the piloting of the GRACE within a randomised trial of a coping intervention. RESULTS: Of the 265 @entity1 who completed and returned their baseline questionnaire (prior to being informed of their level of genetic risk), 257 completed the GRACE. The most highly endorsed sources of stress involved concerns relating to family members, endorsed by over 60% of respondents, and concerns about how the @entity1 would cope if found to be at increased risk (59%). @entity1 made use of multiple coping strategies across different sources of stress. The most frequently reported coping strategies were emotion-focused, which may reflect the stage of the assessment process. CONCLUSION: The completion rates for the matrix and specificity of responses provided suggest that the GRACE may be an acceptable measurement tool. Further data collection and validation is ongoing.

title: The development of a XXXX genetic-specific measure of coping: the GRACE.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity1 :: ('9606', 'Species') :: ['Participants', 'participants']

answer: @entity5 :: (MESH:D009369,Disease) :: ['cancer']


abstract: @entity17829 is a @entity79 . The underlying causes of SAPHO are poorly understood, and treatment is, therefore, directed towards the individual symptoms. However, many @entity1 are refractory to treatment, and new treatment options are needed. Herein, we describe a 28-year-old @entity1 with @entity17829 and @entity709 seen at our hospital. Treatment was initiated with non-steroidal anti-inflammatory drugs, but clinical improvement was poor. The addition of @entity3378 and oral @entity561 also failed to alleviate symptoms. We subsequently commenced treatment with adalimumab 40 mg every 15 days and suspended @entity171 . Following 4 weeks' treatment with adalimumab, there was clear articular improvement and disappearance of @entity75 . Nocturnal @entity158 and global disease assessment were also improved. To our knowledge, this is the first report on the use of adalimumab for SAPHO. More studies are required to confirm our findings.

title: Successful treatment of XXXX with adalimumab: a case report.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity171 :: ('MESH:D004164', 'Chemical') :: ['bisphosphonates']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['palmoplantar pustulous lesions']

entities_list: @entity561 :: ('MESH:D019386', 'Chemical') :: ['alendronate']

entities_list: @entity17829 :: ('MESH:D020083', 'Disease') :: ['SAPHO syndrome']

entities_list: @entity709 :: ('MESH:D007645', 'Disease') :: ['palmoplantar pustulosis']

entities_list: @entity79 :: ('MESH:D001847', 'Disease') :: ['disorder involving the skin, bone and joints']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['inflammatory lumbar pain']

entities_list: @entity3378 :: ('MESH:D012460', 'Chemical') :: ['sulfasalazine']

answer: @entity17829 :: (MESH:D020083,Disease) :: ['SAPHO syndrome']


abstract: @entity3452 level is relatively stable in each individual and is mainly under genetic control. Attempts made to lower @entity3452 with pharmacological means gave conflicting results. In order to further evaluate the effect of hypocholesterolemic drugs on @entity3452 level, 66 @entity1 with primary @entity1007 were selected. The vast majority of the @entity1 had @entity3452 concentration at the low end of the range of distribution, 7 had undetectable @entity3452 levels and only 2 had @entity3452 higher than 30 mg/dl. No relationship was found between @entity3452 level and serum and lipoprotein lipids. In 12 patients serum @entity165 was well controlled by diet alone and the @entity1 continued the diet for up to 8 months. The other @entity1 were randomly subdivided into 3 groups of therapy. The first group received slow release @entity10569 400 mg once a day, the second one @entity8673 20 mg once a day and the third one @entity3413 10-40 mg once a day. Drug therapy lasted for 8 months. At the end of the period, 22 of 29 @entity1 treated with the 2 @entity2453 reductase inhibitors had @entity3452 higher than baseline. The difference was statistically significant in both groups of @entity1 . No significant change in @entity3452 was observed in diet and in @entity10569 group. Serum and LDL @entity165 significantly decreased in all the 3 drug groups. The increase in @entity3452 after the 2 @entity2453 reductase was small enough to have negligible effects on cardiovascular risk, but raises the problem of the role of @entity754 in the catabolism of @entity3452 .

title: Effects of @entity10569 and of 2 @entity2453 reductase inhibitors on lipoprotein (a) level in hypercholesterolemic XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1007 :: ('MESH:D006937', 'Disease') :: ['hypercholesterolemia']

entities_list: @entity3413 :: ('MESH:D019821', 'Chemical') :: ['simvastatin']

entities_list: @entity10569 :: ('MESH:D001629', 'Chemical') :: ['bezafibrate']

entities_list: @entity8673 :: ('MESH:D017035', 'Chemical') :: ['pravastatin']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: Seven new species of spiders of the @entity9497 , all from China, are described. This genus previously included only three species, also only known from China. The new species are: Wolongia bicruris @entity8891 ., Wolongia bimacroseta @entity8891 ., Wolongia erromera @entity8891 ., Wolongiafoliacea @entity8891 ., Wolongia nutica @entity8891 ., Wolongia renaria @entity8891 ., and Wolongia tetramacroseta @entity8891 . Descriptions of the seven new species and diagnoses for all ten species in the genus are given. In addition, we provide distributional data and an identification key to the species.

title: The spiders of the XXXX Zhu, Kim _ Song, 1997 from China (Araneae: Tetragnathidae).

entities_list: @entity9497 :: ('MESH:D056305', 'Disease') :: ['genus Wolongia']

answer: @entity9497 :: (MESH:D056305,Disease) :: ['genus Wolongia']


abstract: BACKGROUND: There is increasing evidence that cognitive-behavioural therapy can be an effective intervention for @entity1 experiencing drug-refractory positive symptoms of @entity161 . AIMS: To investigate the effects of cognitive-behavioural therapy on in- @entity1 with treatment- @entity716 . METHOD: Manualised therapy was compared with supportive counselling in a randomised controlled study. Both interventions were delivered by experienced psychologists over 16 sessions of treatment. Therapy fidelity was assessed by two independent raters. @entity1 underwent masked assessment at baseline, after treatment and at 6 months' follow-up. Main outcome measures were the Positive and Negative Syndrome Scale and the Psychotic Symptoms Rating Scale. The analysis was by intention to treat. RESULTS: @entity1 receiving cognitive cognitive-behavioural therapy had improved with regard to @entity2167 and illness insight at the post-treatment assessment, but these findings were not maintained at follow-up. CONCLUSIONS: Cognitive-behavioural therapy showed modest short-term benefits over supportive counselling for treatment-refractory positive symptoms of @entity161 .

title: Cognitive-behavioural therapy for XXXX of @entity161 resistant to atypical antipsychotic medication. Randomised controlled trial.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Participants']

entities_list: @entity161 :: ('MESH:D012559', 'Disease') :: ['schizophrenia']

entities_list: @entity716 :: ('MESH:D011605', 'Disease') :: ['refractory psychotic symptoms']

entities_list: @entity2167 :: ('MESH:D006311', 'Disease') :: ['auditory hallucinations']

answer: @entity716 :: (MESH:D011605,Disease) :: ['refractory psychotic symptoms']


abstract: PURPOSE: To evaluate the role of @entity4346 ( @entity4346 ), left ventricular systolic function an other clinical parameters on prevalence and complexity of @entity943 in @entity101 . METHODS: @entity943 were studied in 39 @entity101 by 24 hours ambulatory electrocardiographic monitoring. Frequency and complexity of @entity943 were compared among 3 groups: A and B, respectively without and with @entity4346 , both with normal left ventricular function; and C with @entity4346 and @entity299 . @entity4346 and @entity299 were established echocardiographically. Linear regression analysis was performed in order to identify an independent correlation between clinical parameters and presence of @entity943 . RESULTS: Group C @entity1 were older and had significantly higher @entity551 , greater mass index, diastolic posterior wall thickness and end-systolic stress and increased prevalence of electrocardiographic strain. Left ventricular diastolic diameter in C group @entity1 was increased only when compared to A group. Frequencies of cases with more than 10 ectopic ventricular beats/hour, pairs and nonsustained @entity1165 episodes were all significantly increased in C when compared to B and to A. However, only left ventricular mass index or diastolic posterior wall thickness identified independently @entity1 with @entity943 . CONCLUSION: @entity4346 is the main predictor of potential high risk rhythm disturbances in @entity101 .

title: [The role of hypertrophy and left ventricular function on the occurrence of @entity943 in arterial XXXX ].

entities_list: @entity1165 :: ('MESH:D017180', 'Disease') :: ['ventricular tachycardia']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertensives', 'hypertension']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['systolic and diastolic blood pressures']

entities_list: @entity4346 :: ('MESH:D017379', 'Disease') :: ['Left ventricular hypertrophy', 'left ventricular hypertrophy', 'LVH']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['systolic dysfunction']

entities_list: @entity943 :: ('MESH:D001145', 'Disease') :: ['ventricular arrhythmias', 'Ventricular arrhythmias', 'arrhythmias']

answer: @entity101 :: (MESH:D006973,Disease) :: ['hypertension']


abstract: BACKGROUND: Activity and efficacy of liposomal @entity2379 have been established for the treatment of severe @entity364 . Nephrotoxic side effects, especially during prolonged administration, are regarded as a major disadvantage. In this study we examined the response rates and side effects, particularly nephrotoxicity, of treatment with liposomal @entity2379 in a large cohort of @entity1 . @entity1 AND METHODS: 406 @entity1 treated with liposomal @entity2379 between January 1999 and August 2003 in participating German hospitals were included. Documentation included demographic and clinical data, reason for the treatment with liposomal @entity2379 , length of treatment, response to antifungal treatment and side effects. RESULTS: 42.4% of the 406 @entity1 were females. Their ages ranged from 1 day to 77 years. 83 % of the @entity1 had @entity5 and 65.5 % had fever of unknown origin (FUO). Mean duration of treatment with liposomal @entity2379 was 20 +/- 20 days, at an average dose of 2.3 mg/kg/d. 209 @entity1 (51.5 %) showed complete response (CR),105 @entity1 (25.9 %) partial response (PR) and 51 (12.6 %) @entity1 died during the observation. 80.0 % of @entity1 with FUO showed complete or partial response of symptoms. Mean serum @entity1011 increased from 0.9 mg/kg before start of therapy with liposomal @entity2379 to 1.1 mg/kg during treatment. Side effects (common @entity137 criteria > grade 1) occurred in 94 @entity1 (23/2 %). Among these @entity1371 (6.2 %) and @entity409 (5,2 %) were the most common. Nephrotoxicity was documented in 17 @entity1 (4.2 %). CONCLUSION: Liposomal @entity2379 is a safe and efficacious antifungal drug in the treatment of severe invasive @entity364 and fever of unknown origin. Nephrotoxicity is usually not a limiting factor when using liposomal @entity2379 , if it is administered in approved dosage.

title: [Liposomal @entity2379 in the treatment of severe XXXX . Results of a clinical cohort trial].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity2379 :: ('MESH:D000666', 'Chemical') :: ['amphotericin B']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancies']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['liver damage']

entities_list: @entity364 :: ('MESH:D009181', 'Disease') :: ['fungal infections']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']

entities_list: @entity1371 :: ('MESH:D007008', 'Disease') :: ['hypokalemia']

answer: @entity364 :: (MESH:D009181,Disease) :: ['fungal infections']


abstract: Pegylated interferon and @entity2816 demonstrate immunomodulatory and antiangiogenic activity, and efficacy in @entity320 . The combination was evaluated in a phase II trial. Eligibility included biopsy-confirmed @entity320 with @entity3 and progression, maximum of two earlier systemic therapies, performance status of 0-2, and adequate hepatic, bone marrow and renal function. Pegylated interferon was administered at a dose of 0.5 microg/kg subcutaneously weekly and @entity2816 200 mg orally daily. @entity137 was evaluated every 2 weeks and response every 8 weeks. Eighteen @entity1 were enrolled in this trial. Median age was 55.5 years (range: 29-80 years). Seventeen @entity1 had visceral @entity3 and one had lymph node-only @entity3 . Two @entity1 had brain @entity3 . Nine @entity1 had received earlier adjuvant therapy and 16 @entity1 had received earlier therapy for @entity3 . Performance status was 0, 1 and 2 in 11, six and one @entity1 , respectively. Severe (grade 4) @entity137 observed were @entity417 in two @entity1 and @entity882 in one @entity1 . No treatment-related @entity204 occurred. Dose escalation of @entity2816 to 300 mg daily was feasible in four @entity1 . One therapy-related hospitalization for @entity390 and @entity2700 occurred. No objective responses were noted; three @entity1 @entity66 stabilization. The regimen of pegylated interferon and @entity2816 was well tolerated. The combination, however, failed to demonstrate clinical efficacy in pretreated metastatic @entity320 .

title: Phase II trial of pegylated interferon and @entity2816 in malignant XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['Toxicity', 'toxicities']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia']

entities_list: @entity2700 :: ('MESH:D003681', 'Disease') :: ['dehydration']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['demonstrated disease']

entities_list: @entity2816 :: ('MESH:D013792', 'Chemical') :: ['thalidomide']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases', 'metastatic disease']

entities_list: @entity320 :: ('MESH:D008545', 'Disease') :: ['melanoma', 'malignant melanoma']

answer: @entity320 :: (MESH:D008545,Disease) :: ['metastatic melanoma']


abstract: A @entity8593 of the bulbo-membranous urethra had been reported. The @entity1146 extended for 1.5 cm. It presented early in the neonatal period with major dilatation of the upper urinary tracts. After a preliminary urinary diversion, the surgical repair through the perineum was done at the age of 18 months. Such cases are not seen frequently. This @entity1146 must be differentiated from @entity340 , and from other stenoses either iatrogenic, traumatic, or inflammatory. The partial @entity1146 is the only type compatible with life. It may be presented in two forms: annular constriction or extended @entity850 . The mechanism of evolution is not very clear: it is either due to a bad resorption of the urogenital membrane or a defect in the embryogenesis of the urethral tube. Treatment differs according to the site and extent of the lesion simple dilatation, internal urethrotomy, or urethroplasty in one or several stages can be done.

title: [Extensive XXXX of the bulbo-membranous urethra in a child. Apropos of a case discovered in a newborn infant].

entities_list: @entity340 :: ('MESH:D006349', 'Disease') :: ['posterior urethral valves type III']

entities_list: @entity850 :: ('MESH:D003251', 'Disease') :: ['stenosis']

entities_list: @entity8593 :: ('MESH:D007409', 'Disease') :: ['congenital atresia']

answer: @entity850 :: (MESH:D003251,Disease) :: ['congenital stenosis']


abstract: During a seven-year prospective study, 158 humeral shaft @entity174 in 157 @entity1 were treated with closed intramedullary nailing. Only humeral @entity174 not responsive to closed reduction and immobilization and those in noncomplaint @entity1 were eligible. No immobilization was used postoperatively. Seven @entity1 were lost to follow-up. A total of 148 @entity174 healed; there were three nonunions. The average time to clinical union was 7.2 weeks. There were no infections or malunions. Eight of 11 preoperative and three postoperative @entity4542 were lesions in continuity and healed spontaneously. The remaining three had been severed by missiles and needed further attention. Nail withdrawal occurred in eight @entity1 ; five of these needed nail revision. Final range of motion for the elbow averaged 132 degrees and shoulder abduction-external rotation averaged 168 degrees.

title: Closed intramedullary fixation of humeral shaft XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fractures']

entities_list: @entity4542 :: ('MESH:D020425', 'Disease') :: ['radial nerve palsies']

answer: @entity174 :: (MESH:D050723,Disease) :: ['fractures']


abstract: BACKGROUND: @entity1 ' cognitive processing of @entity158 -related information as well as their cognitive, affective and behavioral response pattern when experiencing @entity158 in daily life has been shown to be associated with poorer prognosis in @entity1643 . However, the relationship between specific cognitive processes such as recall of @entity158 and individual @entity158 responses remains unknown. PURPOSE: The present study sought to investigate recall bias in @entity1 with @entity1643 ( @entity1643 ) compared to healthy controls. Furthermore, it was aimed to investigate the impact of @entity1 ' individual @entity158 -related responses on recall bias, comparing fear-avoidance response (FAR), endurance response (ER) and adaptive response (AR) patterns. METHOD: Thirty-one @entity1643 @entity1 and 31 controls were tested on a free recall task with three word lists comprising @entity158 words and neutral words. Further, the @entity1643 group was classified into @entity1 with a FAR, ER and AR pattern, using a short screening including the Avoidance-Endurance Questionnaire (AEQ). Group differences with @entity158 status ( @entity1643 vs. healthy) and AEQ responses (FAR, ER, AR) as between-group factors, word type ( @entity158 vs. neutral) as within-group factor and free recall as dependent variable were analysed by means of repeated-measures analysis of (co-) variance. RESULTS: Results revealed different @entity158 processing of @entity158 words between FAR and ER patterns, whereas @entity1643 @entity1 as a whole did not differ from the healthy controls. FAR @entity1 displayed significantly less recall than ER @entity1 . CONCLUSION: Recall biases in @entity1643 @entity1 are not only a result of experiencing @entity158 but also effected by @entity1 ' @entity158 response pattern with respect to fear-avoidance versus endurance.

title: Recall Bias in @entity1 with XXXX : Individual Pain Response Patterns Are More Important Than Pain Itself!

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity1643 :: ('MESH:D017116', 'Disease') :: ['chronic low back pain', 'low back pain', 'CLBP']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['pain-related material', 'pain']

answer: @entity1643 :: (MESH:D017116,Disease) :: ['Chronic Low Back Pain']


abstract: AIMS: The preconditioning-like @entity1188 -sparing and anti-inflammatory effects of the peptide hormone relaxin following @entity63 have been studied in the heart. Whether reperfusion therapy with recombinant @entity1 @entity7175 , serelaxin, reduces @entity583 size and attenuates the subsequent @entity5704 inflammasome activation leading to further @entity393 following @entity63 /reperfusion (I/R) injury is unknown. METHODS AND RESULTS: After baseline echocardiography, adult male wild-type C57BL or eNOS knockout @entity19 underwent @entity583 ( @entity583 ) by coronary artery ligation for 30   min followed by 24   h reperfusion. @entity19 were treated with either serelaxin (10   g/kg; sc) or saline 1   h prior to @entity63 or 5   min before reperfusion. In both pre-treatment and reperfusion therapy arms, serelaxin improved survival at 24   h post @entity583 in wild-type @entity19 (79% and 82%) as compared with controls (46% and 50%, P   =   0.01), whereas there was no difference in survival between serelaxin- and saline-treated eNOS knockout @entity19 . Moreover, serelaxin significantly reduced @entity1188 size (64% and 67% reduction, P   <   0.05), measured with TTC staining, and preserved LV fractional shortening (FS) and end-systolic diameter (LVESD) in wild-type @entity19 as compared with controls (P   <   0.05). Interestingly, @entity13761 activity in the heart tissue, a measure of inflammasome formation, was markedly reduced in serelaxin-treated wild-type @entity19 compared with controls at 24   h post- @entity583 in both treatment modalities (P   <   0.05). Genetic deletion of eNOS abolished the @entity1188 -sparing and anti-inflammatory effects of serelaxin as well as functional preservation. Serelaxin plasma levels assessed at 5   min and 1   h after treatment, using ELISA, approximated physiologic relaxin levels during pregnancy in @entity19 and parallels that in @entity1 . CONCLUSION: Serelaxin attenuates myocardial I/R injury and the subsequent @entity13761 activation via eNOS-dependent mechanism.

title: Reperfusion therapy with recombinant @entity1 @entity7175 (Serelaxin) attenuates @entity583 size and XXXX inflammasome following @entity63 /reperfusion injury via eNOS-dependent mechanism.

entities_list: @entity1 :: ('9606', 'Species') :: ['humans', 'human']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic injury', 'ischemia']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction', 'MI', 'myocardial infarct']

entities_list: @entity393 :: ('MESH:D034381', 'Disease') :: ['loss of functional myocardium']

answer: @entity5704 :: (114548,Gene) :: ['NLRP3']


abstract: @entity28 is associated with @entity16 . The aim of the study was to evaluate baroreflex sensitivity, an indicator of @entity4148 , in 20 @entity28 @entity1 and adolescents in comparison with 20 age- and sex-matched nonobese subjects. All subjects were examined in the supine position over a period of 50 min. Systolic blood pressure (SBP) and RR intervals were monitored continuously. Baroreflex sensitivity was assessed by cross-spectral analysis of SBP and @entity13198 ( @entity4375 index) and SBP and @entity299 (BRSf index) within the low frequency range (0.04-0.15 Hz). Sensitivity was determined in 3 time intervals of 3 min each to evaluate changes during rest. The @entity4375 index was significantly lower in @entity28 @entity1 and adolescents than in the nonobese control group (p = 0.002). Significant changes in the @entity4375 index over time (p = 0.004) were found only in nonobese subjects. In contrast, the BRSf index increased over time in both groups (p = 0.01), and no significant between-group difference was detected. In conclusion, @entity28 @entity1 and adolescents show decreased resting baroreflex sensitivity with less variation compared with nonobese subjects. The @entity4375 and BRSf indices appear to be only partially correlated.

title: Baroreflex sensitivity is reduced in XXXX normotensive @entity1 and adolescents.

entities_list: @entity1 :: ('9606', 'Species') :: ['children']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['Obesity', 'obese']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['autonomic nervous system dysfunction']

entities_list: @entity4148 :: ('MESH:D001342', 'Disease') :: ['autonomic nervous function']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['heart rate oscillations']

entities_list: @entity13198 :: ('OMIM:610141', 'Disease') :: ['RR interval oscillations']

answer: @entity28 :: (MESH:D009765,Disease) :: ['obese']


abstract: PURPOSE: The aim of this study was to investigate the usefulness of the QUANTEC guideline to prevent @entity2133 after intensity-modulated radiotherapy (IMRT) for @entity135 ( @entity135 ) with respect to follow-up time. In addition, we explored alternative guidelines to further reduce @entity2133 . METHODS: The QUANTEC guideline suggests a mean dose to the contralateral (Dmeancontra) parotid<20 Gy, or Dmeancontra and Dmean to the ipsilateral parotid (Dmeanipsi)<25 Gy. Stimulated whole mouth saliva flow measurements (WMSFM) were conducted at a median of 11 (3-24) months for 63 @entity1 treated with IMRT for @entity135 to a median dose of 70 Gy in 2006-2015. @entity2133 was defined as WMSFM <= 25% post- relative to pre-RT. @entity1 were stratified into a <6m ( @entity2133 : 27% (n=15)), and a 6-24m ( @entity2133 : 19% (n=10)) follow-up group. Dose-response modeling was performed using logistic regression including Dmeancontra, or Dmeancontra and Dmeanipsi. The area under the receiver-operating characteristics curve (AUC) was used to assess discriminative ability, and the agreement between the estimated and observed rate of @entity2133 was given by Spearman's rank correlation coefficient (Rs), and related p-values. RESULTS: Of the non- @entity2133 @entity1 , 65% (<6m) and 56% (6-24m) fulfilled Dmeancontra<20 Gy. The estimated and observed rate of @entity2133 agreed at <6m (AUC=0.78; Rs=0.46; p=0.001), and was 28% at Dmeancontra=20 Gy. A smaller number of non- @entity2133 @entity1 fulfilled the two-gland guideline (33% (<6m) and 26% (6-24m)), but the AUC was higher than using Dmeancontra only (<6m: AUC=0.90; Rs=0.63; p<0.0001; 6-24m: AUC=0.84; Rs=0.25; p=0.08), and the following amendment of the two-gland guideline was suggested: (0.17*Dmeancontra+0.11*Dmeanipsi-8.13)<-1.60 (<6m), and (0.05*Dmeancontra+0.02*Dmeanipsi-3.10)<-1.60 (6-24m). CONCLUSION: The QUANTEC guideline is effective to prevent @entity2133 <6m post-RT, but its usefulness is reduced at later follow-up times. The suggested amendment to the two-gland QUANTEC guideline should be further investigated in an independent cohort of @entity135 @entity1 treated with IMRT.

title: WE-AB-207B-08: Exploring and Refining the QUANTEC Guideline to Reduce Severe Hyposalivation Following IMRT for XXXX .

entities_list: @entity2133 :: ('MESH:D014987', 'Disease') :: ['Severe hyposalivation/xerostomia', 'xerostomia']

entities_list: @entity135 :: ('MESH:D006258', 'Disease') :: ['head and neck cancer', 'HNC']

answer: @entity135 :: (MESH:D006258,Disease) :: ['Head and Neck Cancer']


abstract: AIM: @entity5 ( @entity5 ) are myofibroblastic proliferations occurring in 15% of @entity1 with @entity1412 ( @entity1412 ). Several small series have analysed the incidence of @entity5 and predisposing risk factors. Using meta-analytical techniques, this study aimed to identify risk factors for @entity5 development in @entity1 with @entity1412 . METHOD: Studies of sporadic @entity5 were excluded. The study end-points were the incidence of @entity5 in @entity1412 and @entity5 development by gender, @entity1412 ( @entity1412 ) mutation, family history of @entity5 and previous abdominal surgery. A random effect Mantel-Haenszel model was used to calculate odds ratios for each risk factor and age group. RESULTS: Ten studies of 4625 @entity1 with @entity1412 fulfilled our inclusion criteria. A total of 559 (12%) @entity1 developed @entity5 . Cumulative analysis demonstrated that 80% of @entity5 developed by age 40, the peak incidence rate being in the second and third decades. A positive family history of @entity5 was the most significant risk factor (OR 7.02, 95% CI 4.15-11.9, P < 0.001). An @entity1412 mutation 3' to codon 1399 (OR 4.37, 95% CI 2.14-8.91, P < 0.001) and previous abdominal surgery (OR 3.35, 95% CI 1.33-8.41, P = 0.01) were also implicated. @entity1 were more likely to develop @entity5 (OR 1.57, 95% CI 1.13-2.18, P = 0.007). CONCLUSION: There is consistency amongst @entity1412 registries in documenting the incidence and risk factors for @entity5 development. Having a positive family history for @entity5 is of greater significance than a 3' mutation, suggesting the existence of modifier genes, independent of the @entity1412 genotype-phenotype correlation. Few of these risk factors are modifiable. Delaying prophylactic surgery could be appropriate in female @entity1 with a 3' @entity1412 mutation and @entity536 .

title: Risk factors predicting desmoid occurrence in XXXX with @entity1412 : a meta-analysis.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Desmoid tumours', 'DT']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Women']

entities_list: @entity1412 :: ('MESH:D011125', 'Disease') :: ['familial adenomatous polyposis', 'polyposis', 'adenomatous polyposis coli', 'APC', 'FAP']

entities_list: @entity536 :: ('MESH:C538265', 'Disease') :: ['attenuated polyposis']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: Registration methods combine the anatomic localizing ability of CT or MRI with SPECT images of radiolabeled monoclonal antibodies (Mabs), allowing the accurate staging of @entity1 prior to surgery or following treatment. METHODS: Twenty-four @entity1 (15 males and 9 females, mean age 55 yr, range 29-70 yr) were studied with this technique. Ten @entity1 had suspected @entity14 recurrence and were infused with 10 mCi of 131I-CC49 prior to staging laparotomy. Fourteen @entity1 treated in a Phase I radioimmunotherapy study with 131I-CC49 were also studied. All @entity1 underwent SPECT imaging of the abdomen and pelvis 5-7 days following infusion of Mab. RESULTS: Phantom studies demonstrated a 3.6-mm surface fitting mean accuracy of datasets for the liver and 1.8 mm for an @entity5 . In the presurgical group, SPECT and CT/MRI registration allowed more accurate identification of uptake abnormal sites. Areas of metastatic disease > 1 cm confirmed at surgery were found in six of nine @entity1 with @entity409 and in two @entity1 with extrahepatic (including one @entity1 with pelvic) disease. In @entity1 imaged following radioimmunotherapy, all lesions > 1.5 cm seen on CT/MRI were identified, and activity distribution in @entity5 and normal tissue could be more accurately assessed. CONCLUSIONS: Routine registration of SPECT and CT/MRI images is feasible and allows more accurate anatomic assessment of sites of abnormal uptake in radiolabeled Mab studies.

title: Clinical validation of SPECT and CT/MRI image registration in radiolabeled monoclonal antibody studies of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['liver lesions']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'intrahepatic tumor']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer']

answer: @entity14 :: (MESH:D015179,Disease) :: ['colorectal carcinoma']


abstract: OBJECTIVES: In a cohort of @entity1 with @entity548 ( @entity548 ) secondary to @entity19417 ( @entity19417 ), we aim to identify predictors of @entity1576 and to describe the therapeutic efficacy of plasma exchange (PLEX) and rituximab versus @entity786 in @entity1 with or without @entity1576 . METHODS: Single center historical cohort study of all consecutive @entity1 with @entity19417 -associated @entity548 evaluated over a 16 year period. @entity2357 models were developed to examine the predictive role of the baseline clinical characteristics for the development of @entity1576 , and also for the role of PLEX and induction of remission therapy on the main outcome (complete remission at 6 months). RESULTS: Seventy-three @entity1 with @entity548 were identified of whom 34 @entity1 developed @entity1576 . Degree of @entity519 upon initial presentation, higher neutrophil percentage in the bronchoalveolar lavage fluid cell count, and higher @entity1851 levels were independently associated with the development of @entity1576 . PLEX was not associated with achieving complete remission at 6 months (OR 0.49, 95% CI 0.12-1.95, p=0.32). Rituximab treatment was independently associated with increased odds of achieving complete remission at 6 months (OR 6.45, 95% CI 1.78-29, p=0.003). CONCLUSIONS: The most important predictor of @entity1576 in these @entity1 seems to be the degree of @entity519 upon presentation. A clear benefit of PLEX added to standard remission induction therapy could not be demonstrated. @entity1 with @entity548 secondary to @entity19417 including those requiring mechanical ventilation achieved complete remission by 6 months at a higher rate with rituximab than with @entity786 . This article is protected by copyright. All rights reserved.

title: Diffuse @entity548 secondary to XXXX : Predictors of @entity1576 and clinical outcomes.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity1851 :: ('1401', 'Gene') :: ['C-reactive protein']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['DAH', 'diffuse alveolar hemorrhage']

entities_list: @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide']

entities_list: @entity2357 :: ('MESH:C537770', 'Disease') :: ['Logistic regression']

entities_list: @entity519 :: ('MESH:D000860', 'Disease') :: ['hypoxemia']

entities_list: @entity1576 :: ('MESH:D012131', 'Disease') :: ['respiratory failure']

entities_list: @entity19417 :: ('MESH:D056648', 'Disease') :: ['AAV', 'ANCA-associated vasculitis']

answer: @entity19417 :: (MESH:D056648,Disease) :: ['ANCA-associated vasculitis']


abstract: Thirty-seven eligible @entity1 , median age 59 years (range 37-72) and median performance status 1 (0-2), with advanced, untreated, measurable @entity356 were given @entity1205 , 100 mg m-2 i.v. over 60 min without premedication, once every 3 weeks. Metastatic sites included the liver in 12 @entity1 and retroperitoneal lymph nodes in 16. Eight of the 33 evaluable @entity1 (24%) achieved a partial remission for a median of 7.5 months (3-11+). An additional 11 @entity1 had stabilisation of disease. The @entity1 received a median of four cycles of @entity1205 (range 1-8) for a total of 156 courses. Dose reduction was necessary in 30 cycles; 14 cycles were delayed a mean of 3 days. @entity137 consisted mainly of non-cumulative @entity1398 , with a median nadir count of 0.35 x 10(9) l-1 (0.04-1.64) and eight episodes (5%) of @entity221 ; non-haematological @entity137 included @entity1665 , mild @entity390 and @entity391 and allergic manifestations such as @entity1910 and @entity111 . There were no drug-related @entity204 . Our data indicate that @entity1205 is an active agent in advanced @entity356 ; further clinical investigations seem warranted.

title: XXXX (Taxotere) in advanced @entity356 : results of a phase II clinical trial. EORTC Early Clinical Trials Group.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities', 'Haematological toxicity']

entities_list: @entity221 :: ('MESH:D005334', 'Disease') :: ['leucopenic fever']

entities_list: @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting']

entities_list: @entity111 :: ('MESH:D011537', 'Disease') :: ['pruritus']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia']

entities_list: @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel']

entities_list: @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancer', 'gastric carcinoma']

answer: @entity1205 :: (MESH:C067311,Chemical) :: ['Docetaxel']


abstract: A case of untreated @entity150 with an unusual clinical course in a 48-year-old @entity1 is reported. The @entity1 noted painless gross @entity811 10 months prior to the first visit to our department on May 16, 1980. Cystoscopy revealed @entity5 in the right lateral and posterior wall. The histopathological finding was transitional cell @entity189 , grade II on biopsy. No metastatic lesions were found on clinical evaluation. Therefore, radical cystectomy with ileal conduit was planned. However, the @entity1 refused the operation because he could not tolerate having the stoma on the abdomen. Because the @entity1 had no complaint except for the past gross @entity811 , he refused any treatment. The @entity1 revisited our department 6 months after the diagnosis because swelling of the right thigh caused gait disturbance. A chest X-ray revealed @entity1143 , and an excretory urogram disclosed a right non-visualizing kidney and a large filling defect in the bladder. Cervical lymph nodes were swollen and several small nodules under reddish skin on the chest and abdomen were found to be metastatic lesions. Chemotherapy with @entity900 , @entity632 and @entity1487 was ineffective in regressing the primary @entity5 although cervical lymph nodes and @entity272 responded at the induction. The @entity1 died 29 months after the initial onset of the gross @entity811 and 19 months after the diagnosis. Autopsy findings revealed @entity3 in skin, diaphragm, left adrenal gland, stomach, small intestine, pericardium, right epididymis and lymph nodes.

title: [An autopsy case of untreated XXXX ].

entities_list: @entity1143 :: ('MESH:D010996', 'Disease') :: ['pleural effusion']

entities_list: @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'nonpapillary tumors']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cis-diamminedichloroplatinum']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma']

entities_list: @entity150 :: ('MESH:D001749', 'Disease') :: ['bladder cancer']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

entities_list: @entity272 :: ('MESH:D012871', 'Disease') :: ['skin lesions']

entities_list: @entity811 :: ('MESH:D006417', 'Disease') :: ['hematuria']

entities_list: @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-fluorouracil']

answer: @entity150 :: (MESH:D001749,Disease) :: ['bladder cancer']


abstract: UNASSIGNED: Lifestyle interventions targeting gestational @entity1017 (GWG) report varying degrees of success. To better understand factors influencing efficacy, we reviewed randomized trials specifically among @entity28 and overweight pregnant @entity1 . METHODS: We conducted a systematic review and a meta-analysis of 32 studies with a pooled population of 5,869 overweight or @entity28 pregnant @entity1 . Random effects models were fit to compute the @entity353 ( @entity353 ) in GWG between groups across studies. Subgroup analyses were conducted to compare intervention efficacy in overweight vs. @entity28 pregnant @entity1 , and interventions delivered by prenatal care providers (PCPs) vs. non-PCPs during pregnancy. Moderator analyses ensured. RESULTS: Nine (28%) of 32 studies reported significant reductions in GWG in response to intervention. Of these, six (66%) of nine were delivered by PCPs. Overall, the @entity353 in GWG was -1.71 (95% confidence interval [CI]: -2.55, -0.86)  kg. However, interventions delivered by PCPs yielded a significantly greater reduction in GWG compared to interventions delivered by non-PCPs ( @entity353  =  -3.88  kg; 95% CI: -7.01, -0.75 vs. -0.80  kg; 95% CI: -1.32, -0.28; p for difference  =  0.005). CONCLUSION: When PCPs counsel nutrition and physical activity, @entity28 and overweight pregnant @entity1 have greater success meeting GWG targets and may be more motivated to modify their behaviour than with other modes of intervention deliveries.

title: What characteristics of nutrition and physical activity interventions are key to effectively reducing @entity1017 in @entity28 or overweight pregnant XXXX ? A systematic review and meta-analysis.

entities_list: @entity1017 :: ('MESH:D015430', 'Disease') :: ['weight gain']

entities_list: @entity353 :: ('MESH:D015431', 'Disease') :: ['WMD', 'weighted mean difference']

answer: @entity1 :: (9606,Species) :: ['women']


abstract: BACKGROUND: Matrix metalloproteinases (MMPs) play an important role in @entity296 . Their activity is regulated by the tissue inhibitors of metalloproteinases (TIMPs). The present study analyzed the contribution of changes in functional and molecular parameters to early cardiac remodeling in @entity19 hearts. The role that TIMPs might play in this process was specially acknowledged. METHODS: The remodeling was induced by @entity1063 (NE) given sc in balb/c @entity19 . Varying concentrations, time and the addition of a neutralizing @entity5779 antibody were evaluated. RESULTS: High dose NE led to insufficiency of the left ventricle (LV) as evidenced by reduced NE-induced elevation of LV systolic pressure, contractility and relaxation. Further, signs of @entity358 were seen. NE induced a concentration-dependent increase of LV weight/body weight (LVW/BW) ratio and elevated mRNA expression of @entity14662 (ANP). This was accompanied by induction of collagen type I and III, as well as @entity5779 expression. CONCLUSIONS: The NE-induced increase of @entity5779 expression may induce the elevation of the antihypertrophic cardiac factor ANP since NE-induced increase of ANP expression was abolished by neutralizing @entity5779 antibody. Thus, @entity5779 may mediate ANP-induced attenuation of NE-induced @entity1184 in the @entity19 heart.

title: Tissue inhibitor of matrix metalloproteinase-1 in XXXX -induced remodeling of the @entity19 heart.

entities_list: @entity14662 :: ('230899(Tax:10090)', 'Gene') :: ['atrial natriuretic peptide']

entities_list: @entity296 :: ('MESH:D009202', 'Disease') :: ['myocardial remodeling']

entities_list: @entity1184 :: ('MESH:D006984', 'Disease') :: ['hypertrophy']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['lung congestion']

entities_list: @entity1063 :: ('MESH:D009638', 'Chemical') :: ['norepinephrine']

answer: @entity1063 :: (MESH:D009638,Chemical) :: ['norepinephrine']


abstract: 386 strains of @entity796 isolated in the "F. Veneziale" Hospital Laboratory and Public Health Laboratory in Isernia (Italy) from April 1982 to September 1984 were examined by serological typing according to Habs scheme. Susceptibility to 16 antibiotics was evaluated for 214 of them with the ABAC system. Strains from hospitalized @entity1 were also considered for isolation site and hospital service. Among the 14 different serotypes isolated the O12 serotype ranked first accounting for 31.6% of all isolates. Only 25 strains were untypable (6.5%). @entity2890 resulted the most effective antibiotic in inhibiting Ps. aeruginosa in vitro. No clear relationship was found between serotypes and antibiotic susceptibility patterns. Hospital strains showed marked antibiotic resistance compared to community strains from both @entity1 and healthy carriers. Temporal analysis of antibiograms revealed an increasing incidence of resistant Ps. aeruginosa over time. The spread of antibiotic resistance, however, involved mainly hospital strains and was confined to @entity581 and anti- @entity796 beta-lactam agents.

title: [Microbiological study of 386 strains of XXXX isolated in a 30-month span in the Isernia area with special reference to an antimicrobial assay carried out with the ABAC system on 214 of them].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity2890 :: ('MESH:D014031', 'Chemical') :: ['Tobramycin']

entities_list: @entity796 :: ('287', 'Species') :: ['Pseudomonas aeruginosa', 'Pseudomonas']

entities_list: @entity581 :: ('MESH:D000617', 'Chemical') :: ['aminoglycosides']

answer: @entity796 :: (287,Species) :: ['Pseudomonas aeruginosa']


abstract: @entity8156 (HQ) is a @entity7935 metabolite that is involved in hematopoiesis via its accumulation into bone marrow. HQ also acts as a toxic agent that influences various immune responses. Both neutrophils and eosinophils function as important leukocytes in immunological regulation and @entity1200 . In this study, we examined the toxic effects of HQ on the apoptosis of @entity1 neutrophils and eosinophils isolated from the blood of healthy donors. HQ markedly increased the apoptosis of neutrophils and eosinophils in a concentration- and a time-dependent manner. The pro-apoptotic effect is involved in activation of @entity8187 and @entity522 . Reactive @entity26 species (ROS) production was enhanced after HQ treatment in a dose-dependent manner. In addition, HQ upregulated the release of @entity687 and @entity2842 from neutrophils and eosinophils, respectively. Taken together, the results of this study demonstrated that HQ strongly induces the apoptosis of neutrophils and eosinophils through the @entity8187 /3-dependent pathway and the increased ROS production. HQ exerts a cytotoxic effect in @entity1 neutrophils and eosinophils and may impair the regulation of immune responses.

title: The pro-apoptotic effect of XXXX in @entity1 neutrophils and eosinophils.

entities_list: @entity8156 :: ('MESH:C031927', 'Chemical') :: ['Hydroquinone']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity1200 :: ('MESH:D007154', 'Disease') :: ['immune diseases']

answer: @entity8156 :: (MESH:C031927,Chemical) :: ['hydroquinone']


abstract: Malignant transformation of cells is associated with enhanced proliferation and alterations in @entity268 -dependent protein kinase (PKA) activity. To investigate the role of PKA in normal colonic cell proliferation, PKA was characterized in @entity35 colonic mucosa. In addition, @entity35 were fed diets containing different fats ( @entity4336 oil, fish oil) and fibers (pectin, cellulose, fiber free) to elicit varying levels of colonic cell proliferation in order to study this signaling system under normal physiologic conditions. Overall, PKA activities were higher in cytosolic compared to membrane fractions. PKA type II (PKA II) isozyme contributed 89 +/- 1% and 96 +/- 1% of total PKA activity in cytosolic and membrane fractions, respectively. Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis revealed the presence of mRNA for both the alpha and beta isoforms of the regulatory subunits of PKA II. PKA activities were 21-33% higher in distal membrane and total distal fractions in @entity35 fed a cellulose/ @entity4336 oil diet compared to animals consuming the other fiber/fat diets. These effects were seen only in the distal colon, where the number of cells per crypt column was elevated only in animals fed the cellulose/ @entity4336 oil diet relative to other diets. Diet-induced mitogenic responses did not involve significant changes in the relative activity of PKA I and II isozymes. These data demonstrate that dietary effects on PKA activity in the distal colon may be related to changes in cell differentiation as indicated by the number of cells per crypt column.

title: Dietary modulation of @entity35 colonic XXXX -dependent protein kinase activity.

answer: @entity268 :: (CHEBI:17489,Chemical) :: ['cAMP']


abstract: OBJECTIVES: @entity1205 -based chemotherapy is effective in @entity1 with @entity263 ( @entity263 ). This phase II study assessed the outcome and predictive factors for prognosis and @entity137 following intermittent chemotherapy with @entity1205 , @entity13950 , and @entity3003 ( @entity6567 ) in @entity1 with @entity263 . METHODS: Thirty-five @entity1 were treated with a @entity6567 regimen that consisted of a 28-day cycle of drugs as follows: @entity1205 (60 mg/m(2) on day 1), @entity3003 (AUC 5 on day 1) and @entity13950 (560 mg daily). Treatment was continued intermittently. The end point was to test the effect of @entity6567 on the response rate and @entity1349 ( @entity1349 ). Statistical correlations between the outcomes and predictive factors, including clinical parameters and 8 single-nucleotide polymorphisms (SNPs) related to drug metabolism, were assessed. RESULTS: @entity1486 levels decreased by more than 30% in 65.7% of the @entity1 . The median @entity1349 following @entity6567 was 17.8 months, and the median total time of chemotherapy holiday was 7.7 months (range 1.7-35.8). On multivariate analysis, serum @entity880 dehydrogenase (LDH) was an independent prognostic factor for @entity1349 (p = 0.007). On SNP analysis, @entity1 carrying the TT genotype of the @entity1262 @entity7658 polymorphism showed a significantly more severe @entity1431 during the first cycle of @entity6567 therapy compared to @entity1 with the CC + CT genotype (p = 0.036). CONCLUSION: Combination chemotherapy with @entity6567 has a potential effect on @entity263 with acceptable @entity137 . Serum LDH may be a promising predictor of prognosis, and the @entity1262 @entity7658 polymorphism may be a genetic predictor of the severity of @entity1431 in @entity1 with @entity263 treated with @entity6567 .

title: Outcome, clinical prognostic factors and genetic predictors of adverse reactions of intermittent combination chemotherapy with @entity1205 , @entity13950 and @entity3003 for XXXX .

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity263 :: ('MESH:D011471', 'Disease') :: ['castration-resistant prostate cancer', 'CRPC']

entities_list: @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin']

entities_list: @entity13950 :: ('CHEBI:68643', 'Chemical') :: ['estramustine phosphate']

entities_list: @entity880 :: ('MESH:D019344', 'Chemical') :: ['lactate']

entities_list: @entity1431 :: ('MESH:D007970', 'Disease') :: ['leukocytopenia']

entities_list: @entity1486 :: ('354', 'Gene') :: ['Prostate-specific antigen']

entities_list: @entity1205 :: ('MESH:C067311', 'Chemical') :: ['Docetaxel', 'docetaxel']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']

answer: @entity263 :: (MESH:D011471,Disease) :: ['castration-resistant prostate cancer']


abstract: BACKGROUND: Established prognostic factors influencing survival in soft @entity242 include @entity5 stage, histopathologic grade, size, depth, and anatomic site. The presence of @entity5 near or at the margin of resection increases the risk of local recurrence but whether a positive surgical margin or local recurrence affect overall survival is controversial. QUESTIONS/PURPOSES: We explored the impact of microscopic margin on local recurrence, @entity3 , and overall survival in @entity1 with intermediate- to high-grade soft @entity242 of the extremities. We then determined whether local recurrence decreases overall survival. METHODS: We retrospectively reviewed the medical records of 248 @entity1 who had soft @entity242 of the extremities treated surgically from 1995 to 2008. We estimated survival, local recurrence, and distant @entity3 and examined factors potentially influencing these outcomes. The minimum followup was 0.4 years (median, 4.4 years; range, 0.4-13 years). RESULTS: The 5-year cumulative incidence of local recurrence was 4.1%. @entity1 who presented with positive margins or a margin of 2 mm or less had a worse survival than @entity1 who had margins of greater than 2 mm and wide margins (5-year survival, 47% versus 70% and 72%). In addition to surgical margin, developing @entity3 , @entity5 response of less than 90% @entity39 , high histopathologic grade, high AJCC stage (Stage III), increasing age, and male gender were associated with decreased overall survival. Local recurrence independently predicted decreased overall survival. CONCLUSIONS: Microscopic surgical margin and local recurrence after surgical treatment should be included as risk factors predicting decreased overall survival for intermediate- to high-grade soft @entity242 of the extremities.

title: Do surgical margin and local recurrence influence survival in soft XXXX ?

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity242 :: ('MESH:D012509', 'Disease') :: ['tissue sarcomas']

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

answer: @entity242 :: (MESH:D012509,Disease) :: ['tissue sarcomas']


abstract: PURPOSE: To assess the prevalence of periodontal @entity32 on the distal side of second molars after third molar removal and the association between presurgical and surgical variables and postsurgical periodontal outcomes. @entity1 AND METHODS: Data before and after surgery from 2 studies approved by an institutional review board were used. In 1 study, 26 subjects had 4 asymptomatic third molars and in the other 49 subjects had at least 1 mandibular third molar with symptoms of @entity23029 . Full-mouth periodontal probing data, 6 sites per tooth, were obtained as a measurement of periodontal status before and after surgery. A @entity92 ( @entity92 ) >= 4 mm on either of the 2 possible probing sites on the distal side of any second molar ( @entity23030 ) served as an indicator of periodontal @entity32 ; periodontal health was defined as all D2M @entity92 <4 mm. Cochran-Mantel-Haenszel row mean score tests compared the subjects' postsurgical periodontal status (all D2M @entity92 <4 mm and at least 1 D2M @entity92 >= 4 mm) with respect to age and time intervals, and the Fisher exact test was used to compare ethnicity, gender, and clinical data at surgery. The McNemar test was used to assess the discordance between subjects' pre- and postsurgical periodontal status. The level of significance was set at .05. RESULTS: Of the 75 subjects, 52% were @entity1 and 65% were white. The median age at surgery was 23.6 years (interquartile range, 20.9 to 26.6 years). At enrollment, 53 of 75 subjects (71%) had at least 1 D2M @entity92 >= 4 mm. Subjects were significantly more likely to have an improved D2M periodontal status after surgery than a deteriorated status (P < .01). Fewer subjects, 17 of 75 (24%), had at least 1 D2M @entity92 >= 4 mm after surgery. D2M @entity92 >= 4 mm was more likely after surgery if presurgical D2M was @entity92 >= 4 mm (P < .01). Gender, ethnicity, age, presurgical symptoms, and data estimating the extensiveness of surgery were not significantly associated with postsurgical D2M periodontal outcomes. CONCLUSIONS: After third molar removal, periodontal @entity32 on the distal of D2Ms was detected significantly less often. None of the variables examined except for presurgical presence of D2M @entity92 >= 4 mm were significantly associated with postsurgical D2M periodontal @entity32 .

title: Second molar periodontal XXXX after third molar removal in young adults.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'PATIENTS']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammatory disease']

entities_list: @entity23029 :: ('MESH:D010497', 'Disease') :: ['pericoronitis']

entities_list: @entity23030 :: ('p|SUB|D|2|M', 'ProteinMutation') :: ['D2M']

entities_list: @entity92 :: ('MESH:D007222', 'Disease') :: ['PD', 'probing depth']

answer: @entity32 :: (MESH:D007249,Disease) :: ['inflammatory disease']


abstract: PURPOSE: The objective of present work was to develop a @entity3913 -anchored, engineered nanoparticulate system for efficient delivery of @entity2379 to macrophages. Furthermore, the effect of spacer on macrophage targeting was also evaluated. METHODS: @entity7050 was conjugated to @entity3913 via direct coupling (M- @entity7050 ) and via @entity970 spacer ( @entity12389 ), and engineered @entity7050 nanoparticles (M-PNPs and M- @entity970 -PNPs) were prepared from respective conjugates. These prepared engineered PNPs were characterized for size, polydispersity index (PDI), surface charge, and drug entrapment efficiency (% DEE). Transmission electron microscopy (TEM) and atomic force microscopy (AFM) were employed to study the shape and surface morphology of engineered PNPs. Macrophage targeting was evaluated via cellular uptake, ex vivo antileishmanial activity and in vivo biodisposition pattern of engineered PNPs in macrophage-rich organs. RESULTS: The developed engineered PNPs were found to be of nanometric size (<200 nm) and to have low PDI (<0.162) and good entrapment efficiency (%DEE >53.0%). AFM and TEM revealed that both M-PNPs and M- @entity970 -PNPs had smooth surface and spherical topography. Engineered PNPs with spacer showed enhanced uptake, potential antileishmanial activity and higher disposition in macrophage-rich organs, suggesting improved macrophage targeting. CONCLUSIONS: The results suggest that engineering of nanoparticles could lead to development of efficient carrier for macrophage targeting.

title: Preparation, characterization and evaluation of targeting potential of XXXX -loaded engineered @entity7050 nanoparticles.

entities_list: @entity2379 :: ('MESH:D000666', 'Chemical') :: ['amphotericin B']

answer: @entity2379 :: (MESH:D000666,Chemical) :: ['amphotericin B']


abstract: BACKGROUND: Acute cardiac allograft rejection requires host, but not donor, expression of @entity8271 / @entity11787 costimulatory molecules. However, acute cardiac rejection requires direct antigen presentation by donor-derived antigen presenting cells to @entity1961 T-cells and does not require indirect antigen presentation to @entity1961 T-cells. Given this discrepancy in the literature and that the consequence of allograft exposure in @entity942 @entity19 is unknown; the goal of the study was to examine the antidonor status of allografted @entity8271 / @entity11787 -deficient hosts. METHODS: C57Bl/6 @entity8271 / @entity11787 -/- @entity19 were grafted with heterotopic BALB/c hearts. Recipients bearing long-term surviving allografts were used to examine the status of antidonor reactivity in vitro and in vivo. Tolerance was examined in vivo through adoptive transfer of splenocytes from graft-bearing animals to secondary immune-deficient @entity5350 -/- hosts bearing donor-type or third-party cardiac allografts and by regulatory T-cell depletion with anti- @entity3783 antibody. RESULTS: When transferred to B7-replete @entity5350 -/- recipients, cells from na  ve @entity8271 / @entity11787 -/- @entity19 readily initiated cardiac allograft rejection. However, splenocytes transferred from long-term allograft acceptor @entity8271 / @entity11787 -/- hosts failed to reject donor-type hearts but acutely rejected third-party allografts. In addition, such cells did not reject (donorxthird-party) F1 allografts. Finally, in vivo depletion of regulatory T-cells did not prevent long-term acceptance. CONCLUSIONS: Results demonstrate that @entity942 T-cells are capable of acute cardiac allograft rejection in a B7-replete environment. Importantly, results also show that @entity942 hosts do not simply ignore cardiac allografts, but rather spontaneously develop transferable, donor-specific tolerance and linked suppression in vivo. Interestingly, this tolerant state does not require endogenous @entity1961 + @entity3783 + regulatory T-cells.

title: Spontaneous allograft tolerance in @entity942 @entity19 independent of preexisting endogenous XXXX + @entity3783 + regulatory T-cells.

entities_list: @entity942 :: ('MESH:D003677', 'Disease') :: ['B7-deficient']

answer: @entity1961 :: (12504(Tax:10090),Gene) :: ['CD4']


abstract: Troublesome perianal disease occurs in approximately 35% of @entity1 with @entity30 , yet conventional disease activity indices do not reflect the severity of this feature. To assess the degree of impairment and response to therapy, we identified five simple elements and graded each on a 5-point Likert scale in 37 @entity1 at 124 visits. At each visit a @entity30 (CDAI) or Simple Activity Index (HBDAI), @entity66 Activity Index (PDAI), and treatment were recorded. The PDAI was validated against physician (MDGA) and @entity1 (PGA) global assessments, and treatment was prescribed for the perianal disease. Measurement error was evaluated in 19 @entity1 who were clinically stable at two consecutive visits. The ability of the PDAI to detect important clinical change was tested in 20 subjects exhibiting a change on @entity6987 at consecutive visits. There were strong correlations between PDAI, @entity19254 , and PGA scores at all visits (R = 0.66-0.72; p < 0.001), whereas the CDAI and HBDAI correlated poorly with PDAI (R < 0.23). Physicians prescribed more aggressive therapy for higher PDAI scores (r = 0.53). Mean PDAI scores between visits in clinically stable subjects were not significantly different [5.58 +/- 2.79 (initial); 5.42 +/- 2.55 (follow-up); p = 0.63]. PDAI significantly improved between visits when the perianal disease had improved (PDAI score difference 3.05 +/- 2.96; P = .0002). We conclude that the PDAI is simple and clinically useful for @entity1 management. It should now be assessed in a clinical trial.

title: Usual therapy improves perianal XXXX as measured by a new disease activity index. McMaster IBD Study Group.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['Perianal Disease']

entities_list: @entity30 :: ('MESH:D003424', 'Disease') :: ["Crohn's Disease", "Crohn's disease"]

answer: @entity30 :: (MESH:D003424,Disease) :: ['Crohn's disease']


abstract: Of 66 cases of @entity2649 for @entity1691 , 59 were @entity1 and seven were @entity1 with a follow-up period of two to 30 years after surgery. Their ages ranged from 19 to 55 years. The deformity was corrected by a one-stage posterior osteotomy and decompression of the posterior elements of the spine. @entity86 , @entity390 , @entity391 , and urinary retention were the most common surgical complications. There were no cases of permanent @entity51 . The one fatality occurred on the ninth postoperative day because of a ruptured aorta. The results were gratifying in the 65 remaining cases. These @entity1 were pleased with the cosmetic results, improved gait, and ability to look straight ahead. In addition to the expanded field of vision, there was general improvement in the @entity344 plus a better mental attitude. @entity1 over 55 years of age, @entity1 with @entity730 , poor medical risks, and @entity1 with ankylosed hips (untreated with total hip arthroplasties) are contraindications for this operation.

title: Corrective osteotomy of the spine in XXXX . Experience with 66 cases.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients', 'men']

entities_list: @entity2649 :: ('MESH:C563613', 'Disease') :: ['corrective lumbar osteotomy']

entities_list: @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting']

entities_list: @entity344 :: ('MESH:D005767', 'Disease') :: ['cardiorespiratory and gastrointestinal functions']

entities_list: @entity730 :: ('MESH:D002114', 'Disease') :: ['aortic calcification']

entities_list: @entity51 :: ('MESH:D009461', 'Disease') :: ['neurological deficit']

entities_list: @entity1691 :: ('MESH:D013167', 'Disease') :: ['ankylosing spondylitis']

entities_list: @entity86 :: ('MESH:D019106', 'Disease') :: ['Postoperative ileus']

answer: @entity1691 :: (MESH:D013167,Disease) :: ['ankylosing spondylitis']


abstract: Fourteen @entity1 treated by allogeneic @entity236 ( @entity1860 ) were evaluated by the polymerase chain reaction (PCR) for @entity1861 -specific transcripts. Nine @entity1 were transplanted in the first chronic phase, three in the second chronic phase, and two in the accelerated phase. All @entity1 achieved a complete cytogenetic and hematologic remission after bone marrow transplantation. Twelve @entity1 are alive (median, 18 months; range, 5-54 months) and two @entity1 died early. @entity1861 mRNA was persistently detectable for 6 to 54 months in four @entity1 ( @entity1 1, 3, 4, 6). From two of them, DNA fingerprint analysis showed only donor type DNA although @entity1861 mRNA was detectable. @entity1861 mRNA was never detectable posttransplant in three @entity1 ( @entity1 2, 5, 13). Six @entity1 had detectable @entity1861 mRNA ( @entity1 8-12, 14): by 6 months, all of these @entity1 were @entity1861 mRNA negative. One @entity1 ( @entity1 7) had detectable full @entity1861 mRNA again at 12 months, but was then negative at 20 months. Ten @entity1 ( @entity1 2, 4-8, 10-13) had never detectable Philadelphia ( @entity12297 ) chromosome t(9.22) translocation, whereas four @entity1 had detectable @entity12297 ( @entity1 1, 3, 9, 14); by 6 months, three of four cases were negative. One @entity1 ( @entity1 1) had detectable @entity12297 at 44 months, but was negative at 50 months. Three of six @entity1 who initially had @entity1861 mRNA detectable posttransplant ( @entity1 7-9) became negative for @entity1861 mRNA at the time of development of @entity2132 ( @entity2132 ). These results suggest that the detection of subclinical @entity12297 positive cells by PCR is not associated with imminent clinical or cytogenetic relapse. Moreover, graft-versus- @entity1778 (GVL) activity may contribute to the treatment of minimal @entity66 in @entity1860 after allogeneic bone marrow transplantation.

title: Predicting relapse of XXXX after allogeneic bone marrow transplantation by @entity1861 mRNA and DNA fingerprinting.

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['residual disease']

entities_list: @entity2132 :: ('MESH:D006086', 'Disease') :: ['GVHD', 'chronic graft-versus-host disease']

entities_list: @entity236 :: ('MESH:D001855', 'Disease') :: ['bone marrow transplantation for chronic myelogenous leukemia']

answer: @entity1860 :: (MESH:D015464,Disease) :: ['chronic myelogenous leukemia']


abstract: We measured the wavelength of the cardiac impulse, defined as the distance traveled by the depolarization wave during the functional refractory period, in isolated narrow strips of @entity95 atrium. During control, wavelength was 42 mm during pacing with 2 Hz, and was 28 mm at the maximum pacing rate; early premature beats had a wavelength as short as 23 mm. Administration of @entity5402 (4 X 10(-7) g/ml) shortened the wavelength to 21 mm during 2 Hz, 18 mm at the maximum pacing rate Fmax, and 16 mm during an early premature impulse, respectively. The effects of @entity1425 (6 X 10(-7) M) were strongly rate dependent. At slow heart rates, epinephrine clearly prolonged the wavelength (58 mm), whereas, during maximum pacing, wavelength remained unchanged (28 mm). @entity1371 (2 mM) decreased the length of the impulse at all stimulation frequencies. Moderate @entity4144 (5.6 and 7.0 mM) did not modify wavelength because refractoriness and conduction velocity were affected proportionally. Above 7.0 mM @entity972 , the wavelength became progressively prolonged because of the development of post-repolarization refractoriness. Cooling to 27 degrees C resulted in a slight lengthening of the impulse. At lower temperatures, however, wavelength prolonged significantly because of a relatively strong prolongation of the refractory period. In separate experiments in 15 X 20 mm segments of atrium, reentrant @entity591 were induced and the circuit size compared with the wavelength. The size of intraatrial circuits was similar to the magnitude of the measured wavelength during maximum pacing. @entity5402 and @entity1371 , both of which shorten the impulse length, also clearly decreased the size of reentrant circuits. Cooling to 27 degrees C, which affects both refractoriness and conduction velocity, only slightly prolonged the wavelength; accordingly, the size of reentrant circuits at 27 degrees C was only slightly longer than at 37 degrees C. These experiments emphasize the importance of the wavelength of the cardiac impulse in relation to the occurrence of intramyocardial reentry.

title: The wavelength of the cardiac impulse and reentrant arrhythmias in isolated XXXX atrium. The role of heart rate, autonomic transmitters, temperature, and @entity972 .

entities_list: @entity1425 :: ('MESH:D004837', 'Chemical') :: ['epinephrine']

entities_list: @entity591 :: ('MESH:D013610', 'Disease') :: ['tachyarrhythmias']

entities_list: @entity972 :: ('MESH:D011188', 'Chemical') :: ['potassium']

entities_list: @entity1371 :: ('MESH:D007008', 'Disease') :: ['hypokalemia', 'Hypokalemia']

entities_list: @entity5402 :: ('MESH:D002217', 'Chemical') :: ['carbamylcholine', 'Carbamylcholine']

entities_list: @entity4144 :: ('MESH:D006947', 'Disease') :: ['hyperkalemia']

answer: @entity95 :: (9986,Species) :: ['rabbit']